News – Formulytica

05AugAugust 5, 2025

Formulytica leadership change

Formulytica is pleased to announce the appointment of Dr Michael Andrews Luke as Chief Executive Officer (CEO) and Managing Director, effective 23 July 2025, as part of a planned leadership transition. Michael has over 20 years of experience in drug development and R&D leadership across biotech, pharmaceuticals, and cosmetics, and has been a key member of Formulytica's executive team for the past 7 years. Michael succeeds Dr Richard Buchta, who has stepped down as CEO and Managing Director after 10 years. Richard remains with the company as a Non-Executive Director and Advisor. This transition ensures continuity in leadership and positions Formulytica for its next phase of innovation and growth. For more information, read the full announcement.

05MarMarch 5, 2024

Formulytica Conference Schedule for 2024

Formulytica are pleased to share our itinerary of local and international conferences that our team will be attending in 2024. We look forward to connecting with our industry peers and prospective clients as we showcase our capability as an innovative contract development and manufacturing organisation (CDMO) supporting early stage development of topical and injectable drugs. Our itinerary begins in our home city of Melbourne, at the Australia Biologics Festival 2024, 20-21 February. Following this, we will be attending BIO-Europe Spring in Barcelona, 18-20 March, as part of the Global Victoria trade delegation. Continuing our presence at international BIO meetings, we will be at the Asia BIO Partnering Forum in Singapore, 24-25 April, and the BIO International Convention in San Diego, 3-6 June. Back on home shores, we will be exhibiting at the annual ARCS conference in Sydney, 12-14 June, before heading back to Europe to attend two dermatology conferences in September: the European Society for Dermatological Research (ESDR) 53rd Annual Meeting in Lisbon, 4-7 September, and the European Academy of Dermatology and Venereology (EADV) Congress in Amsterdam, 25-28 September.

12AprApril 12, 2023

Formulytica poised to develop clinical-ready formulations of psilocybin and MDMA

Formulytica is pleased to announce that it has been granted a licence from the Victorian Department of Health enabling it to develop new clinical-ready pharmaceutical formulations containing the drugs psilocybin and MDMA (3,4-methylenedioxy-methamphetamine). This news comes following the recent decision by the Therapeutic Goods Administration (TGA) in Australia to change the classification of psilocybin and MDMA, allowing authorised psychiatrists to prescribe them under the Authorised Prescriber Scheme for certain mental illnesses. From 1 July 2023, Psilocybin and MDMA will be classified as Schedule 8 poisons when prescribed by authorised psychiatrists for certain medical conditions. Previously, they were classified as Schedule 9 poisons, meaning they were prohibited from use except for research or analytical purposes. The change in classification is based on growing evidence that psilocybin and MDMA may have therapeutic benefits for a range of mental health conditions, including treatment-resistant depression and post-traumatic stress disorder. Formulytica is excited about the potential for these drugs to improve the lives of people suffering from these conditions, and is committed to developing safe and effective formulations to support their use. Formulytica specialises in developing innovative drug formulations and analytical methods that are essential for any new medicine entering clinical trials. Our team has a deep understanding of the importance of developing robust formulations and analytical methods to ensure the safety, efficacy, and quality of drug products. With our expertise in developing a wide variety of dosage forms, including topical, oral, and injectable, and our expertise in analytical method development and stability testing, we are well-positioned to support the development of new clinical-ready formulations of psilocybin and MDMA. For more information about the scheduling of poisons in Australia, please refer to the TGA's website. For enquiries, contact us here.

24JunJune 24, 2021

New international patent application

New injectable drug delivery formulation technology
Co-invented by Formulytica and SERI researchers under collaborative research agreement
Potential ‘platform technology’ with broad therapeutic potential

Formulytica (Melbourne, Australia) and Singapore Eye Research Institute (SERI; Singapore) are pleased to announce that an international (PCT) patent application was filed in Singapore in May 2021. An outcome of their collaborative research, the patent covers a new drug delivery technology with application for reduction of scarring following eye surgery. This comes after formulation development and in vitro and in vivo proof of concept studies successfully demonstrated the applicability of this formulation technology, which has potentially broad applicability across a range of other therapeutic areas. Further work is ongoing to refine the technology and proceed to pre-clinical safety studies and eventually Phase 1 clinical studies.

About Formulytica Pty Ltd

Formulytica is an Australian innovative technology developer and service provider specialising in topical and injectable formulation development. Formulytica’s services include new product development and it specializes in the analytical science of semi-solid formulations for topical application utilised in dermatology, pharmaceutical, cosmetic, veterinary and personal care products, such as skincare and haircare. Formulytica’s injectable parenteral expertise covers solution and lipid-based formulations, in biologics, as well as small organic molecules. For more information, please visit www.formulytica.com.

About SERI

Established in 1997, the Singapore Eye Research Institute (SERI) is Singapore’s national research institute for ophthalmic and vision research. It is the research arm of the Singapore National Eye Centre, and affiliated to the National University of Singapore and the Duke-NUS Medical School. In two decades, SERI has grown from a team of 5 to over 250 staff, encompassing clinician scientists, scientists, fellows, students, support staff, as well as more than 245 distinguished adjunct faculty members to become the largest eye research institute in the Asia-Pacific region. As of Mar 2021, SERI has published 4,353 peer-reviewed papers supported by S$346 million in competitive research grants. SERI has trained more than 210 current and past graduate students; and has been conferred over 714 national & international awards and 145 patents. SERI further undertakes eye research in collaboration with local & international medical centres and research institutions, which has ensured a high level of research competency & skills transfer. Notably, SERI’s research has translated to actual patient success stories & significant improvements in eye care delivery. Today, SERI is recognized as a pioneering center for high quality eye research in Asia, with breakthrough discoveries that has translated to significant paradigm shift in eye care delivery. For more information, please visit https://www.snec.com.sg/research-innovation/about-seri.

09FebFebruary 9, 2020

Our summer interns 2019-2020

Formulytica has hosted 3 Monash University students for their industry internship. These students are from various backgrounds such as marketing, biomedical science and media communications.

As part of Formulytica’s mission and values, we encourage innovative collaborations to produce exemplary results. Although working on separate projects, our interns have been moving forward as a cohesive unit, all the while gaining experience and expanding their knowledge in their fields. We wish them the very best with their future studies and careers.

10DecDecember 10, 2019

Formulytica participates in the Third Precision Medicine & Medical Care and Aging International Forum in Tianjin, China, December 7-8

Our CEO, Dr Richard Buchta, joined with other international delegates at the Third Precision Medicine & Medical Care and Aging International Forum in Tianjin, China this week. The event, hosted by Beroni Group, had the theme of “Innovation Driving Development, Technology Leading Future”. Scientists, experts and scholars in the healthcare industry from China, America, Japan, Australia presented their latest scientific and technological achievements towards innovative therapies for cancer and aging.

08DecDecember 8, 2019

Austrade delegation at Taiwan Healthcare Expo, December 5-8

Formulytica joined with the Australian Biomedical & Digital Health Showcase hosted by Austrade Taipei as part of the 2019 Taiwan Healthcare+ Expo. The event aims to promote Australian capabilities and build commercial biomedical partnerships between Australia and Taiwan and the region. Our CEO, Dr Richard Buchta, participated in site tours and B2B meetings, and met with a number of prospective new clients in the biotechnology and pharmaceutical industry to discuss their topical and injectable drug formulation needs.

20AugAugust 20, 2019

Richard Buchta to speak at Biotech Development Lab “Formula for Success”, September 13

Formulation is key to the success of any pharmaceutical product. Formulytica’s CEO Dr Richard Buchta will speak about what is required for successful formulation development, technical transfer and scale up, including a number of case studies. Richard is presenting along with a range of other experts at the upcoming 2019 Biotech Development Lab, “Formula for Success”, hosted by BioMelbourne Network at the Victorian Comprehensive Cancer Centre, 13 September. For more information, visit this link.

12AugAugust 12, 2019

Formulytica offers liposomal formulation development services

As part of Formulytica’s expanding offerings in injectable and topical formulation development services, we are pleased to announce that we have the capability to assist our clients in developing liposomal formulations.

Liposomes are small, spherical particles composed of one or more phospholipid bilayers. Due to their small size (typically ranging from 100 to 200 nm in diameter), liposomes are often referred to as nanomedicine or nanotechnology. The size and structure of liposomes can be controlled by their formulation composition, and their method of manufacture. Some of the advantages of liposomes as a drug delivery vehicle are their ability to improve the solubility and stability of poorly water soluble drugs, their ability to increase the therapeutic window and bioavailability of drugs, and their excellent safety profile and biocompatibility.

Please contact us for more information about our liposomal formulation development services.

17JulJuly 17, 2019

Formulytica attends BIO Asia-Taiwan Conference and Exhibition, July 24-28

Formulytica is attending the 2019 BIO Asia-Taiwan International Conference and Exhibition in Taipei, July 24-28 as part of the Austrade delegation.

Be sure to visit the Australian pavilion to chat with our CEO, Dr Richard Buchta, and learn more about how Formulytica can partner with you to develop your topical or injectable formulations.

More about BIO Asia Taiwan:

For the past 16 years, BioTaiwan has established itself as one of the largest annual biotech events in Asia. Expanding on this legacy, the Biotechnology Innovation Organization (BIO) and the Taiwan Bio Industry Organization (Taiwan Bio) have come together to present BIO Asia-Taiwan, taking place July 24-28 in Taipei. Themed “Biotech as the Next Growth Engine for Asia", this year’s event will attract more than 1,500 attendees from 25 countries representing biomedical, pharmaceutical, genomics, biotech services, equipment and instruments, academic research, cosmetology products and bio-based healthcare.